Health Care • Biotechnology: Pharmaceutical Preparations
$44.55 ▼ -1.84
(-3.97%)
MKT CAP: $133.3M • VOL: 90.6K
52W L $38 52W H $129
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$37
MEDIAN
$50
MEAN
$51
HIGH
$61
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SPRB TAPE
SPRB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $53.91 | $51.23 | 2025-02-14 | $40.54 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $56.13 | $52.57 | 2025-02-06 | $41.88 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $50.79 | $49.01 | 2025-01-29 | $42.77 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $45.44 | — | 2025-01-17 | $43.66 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $39.20 | $42.32 | 2025-01-09 | $39.65 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $53.01 | $46.33 | 2024-12-18 | $38.76 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $43.21 | $45.00 | 2024-12-04 | $41.43 | -4.3% | 48% | C |